Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, [...]
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Officials cited data showing the new Alzheimer’s drug has serious [...]
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
The Alzheimer’s Association has pushed relentlessly to get broad access [...]
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decision
Medicare officials are trying to determine whether to cover Aduhelm, [...]
Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstacles
A group of Alzheimer’s experts and health advocates called on [...]
Biogen’s Alzheimer’s drug is unlikely to win E.U. approval.
The drug, Aduhelm, has been mired in controversy since it [...]
Sales of Biogen’s Alzheimer’s Drug Fall Short of Expectations
The drug, Aduhelm, brought in $300,000 in revenue in its [...]
House Committees Demand F.D.A. Records on Alzheimer’s Drug Approval
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” [...]
That $56,000 Drug? Blame Medicare.
For an increasingly important set of drugs, Medicare has been [...]
Biogen’s Aduhelm Sales Total $2 Million in Second Quarter
The drug from Biogen, called Aduhelm, is expected to generate [...]